Zhiqiang Wu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Ejection Fraction

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Xin Yan, Deyun Chen, Xinran Ma, Yao Wang, Yelei Guo, Jianshu Wei, Chuan Tong, Qi Zhu, Yuting Lu, Yang Yu, Zhiqiang Wu, Weidong Han
CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood advances 6 (22) (2022)
Yajing Zhang, Yao Wang, Yang Liu, Chuan Tong, Chunmeng Wang, Yelei Guo, Dongdong Ti, Qingming Yang, Shen Qiao, Zhiqiang Wu, Weidong Han
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. Leukemia (2021)